PLLA Biostimulators Compared: What Separates the Available Options?

Poly-L-lactic acid (PLLA) biostimulators all share one mechanism — resorbable PLLA microparticles trigger fibroblasts to build new collagen over weeks, producing gradual, long-lasting densification and lift. What actually separates the products on the market is everything around that mechanism: PLLA dose per vial, vial and reconstitution format, added ingredients, published longevity and price position. This article compares the options a European clinic realistically evaluates in 2026: Sculptra®, Gana V/X, Rennova Elleva and Reju PLLA.

All third-party specifications below come from the manufacturers' published materials; trademarks are used nominatively, for identification only. Sculptra® is a registered trademark of Galderma ; Alva Medica is not affiliated with Galderma. Alva Medica is the official distributor of the MedRoyal portfolio, which includes Rennova Elleva, Gana and Reju — a commercial relationship readers should weigh as they read.

How does PLLA biostimulation work, in one paragraph?

Injected PLLA microparticles act as a controlled stimulus in the dermis or subdermis: as the material slowly degrades to lactic acid over months, fibroblasts respond with new type-I collagen around each particle. The visible result — density, firmness, gradual volumisation — emerges over 4–8 weeks per session and consolidates across a short series, which is why every PLLA product shares the same consultation script: nothing dramatic on day one, structural change over the following weeks, results measured in years. Where PLLA sits versus HA fillers and other stimulators is mapped in our biostimulators vs fillers guide.

What are the main PLLA products and their published formats?

Figures below are from manufacturer-published data; verify against the current IFU of each product before clinical use.

Three structural patterns stand out. First, the 210/630 mg dose tiering used by both Gana and Rennova Elleva creates a clean split between facial-zone work (210 mg) and full-face or body programmes (630 mg), where per-session consumption is several times higher. Second, Reju PLLA is the composition outlier: its polynucleotide fraction produces a gentle, immediately visible filling effect on day one, closing the "nothing happened" gap that pure PLLA consultations must manage. Third, all of them are professional-use products for qualified practitioners — distribution runs through verified B2B accounts, never retail.

Which format fits which clinic workload?

Dose economics drive the choice more than brand debates. A clinic doing occasional single-zone facial PLLA (temples, cheeks) is served by a 210 mg tier — Rennova Elleva 210 or Gana V. High-volume practices and body-zone programmes (abdomen, buttocks, thighs, décolleté) burn PLLA fast enough that the 630 mg formats become the economical default. Practices whose patients struggle with the delayed-result conversation have a specific reason to look at Reju PLLA: the PN phase gives the patient something to see immediately while the collagen phase builds.

Reconstitution practice differs by product — hydration times, final volumes and dilution schemes are IFU-level parameters, and the biggest operational differences between brands show up here rather than in the syringe. Whichever product you stock, the post-session massage discipline and deep injection plane are non-negotiable across the category.

What does the comparison mean commercially?

For a European buyer, the practical short-list question is usually price-per-milligram of PLLA at your realistic order volume, weighed against reconstitution workflow and patient-facing differentiators (the PN phase, published longevity, brand recognition in your market). As official MedRoyal distributor, Alva Medica quotes Rennova Elleva, Gana and Reju individually per market and volume — browse the biostimulators category, or request wholesale terms if you buy for a clinic group or resale territory.

FAQ

Is a higher PLLA content per vial always better?

No — it is a workload match, not a quality ranking. A 630 mg vial only wins economically if your case mix consumes it within its post-reconstitution usability window; for occasional facial work, a 210 mg tier avoids waste and simplifies dosing discipline.

How is Reju PLLA different from pure-PLLA products?

Reju combines 365 mg of PLLA with polynucleotides in one preparation. The PN fraction gives an immediate light filling and its own regenerative contribution; the PLLA fraction delivers the long-term collagen phase. Pure-PLLA products concentrate everything in the delayed structural phase.

How long do PLLA results actually last?

Manufacturer-published figures across the category cluster at roughly two to three years: Gana and Rennova Elleva publish 2–3 years / 24–36 months, Reju up to 24 months, and Sculptra®'s manufacturer has published results out to about two years. Individual duration varies with age, zone, metabolism and dosing.

Who is allowed to inject PLLA biostimulators?

Qualified aesthetic-medicine practitioners only. These are deep-plane, technique-sensitive products; as distributor we verify professional status during B2B onboarding before first supply, and every clinic should document batch numbers per patient as standard practice.

All third-party product information above is based on manufacturer-published data at the time of writing; nominative trademark use only, no affiliation or endorsement implied. This article compares products factually and makes no claim of clinical superiority of any product over another. Last updated: 2026-08-11.